Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 8 studies | 37% ± 15% | |
hepatocyte | 3 studies | 33% ± 16% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney | 3 studies | 21% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 4920.83 | 226 / 226 | 82% | 23.77 | 331 / 406 |
kidney | 100% | 5900.89 | 89 / 89 | 77% | 39.24 | 694 / 901 |
uterus | 59% | 3.53 | 101 / 170 | 0% | 0.01 | 1 / 459 |
breast | 57% | 3.83 | 260 / 459 | 1% | 0.03 | 7 / 1118 |
adrenal gland | 53% | 2.57 | 137 / 258 | 0% | 0 | 0 / 230 |
skin | 45% | 2.11 | 810 / 1809 | 0% | 0.02 | 1 / 472 |
intestine | 36% | 22.68 | 352 / 966 | 0% | 0.07 | 1 / 527 |
stomach | 34% | 1.13 | 121 / 359 | 0% | 0 | 0 / 286 |
pancreas | 31% | 0.87 | 103 / 328 | 1% | 0.05 | 1 / 178 |
bladder | 29% | 0.95 | 6 / 21 | 0% | 0 | 0 / 504 |
peripheral blood | 28% | 5.16 | 263 / 929 | 0% | 0 | 0 / 0 |
lung | 24% | 0.83 | 137 / 578 | 0% | 0.03 | 2 / 1155 |
prostate | 23% | 0.73 | 57 / 245 | 0% | 0 | 0 / 502 |
heart | 21% | 0.77 | 183 / 861 | 0% | 0 | 0 / 0 |
ovary | 21% | 0.67 | 38 / 180 | 0% | 0 | 0 / 430 |
spleen | 18% | 4.83 | 44 / 241 | 0% | 0 | 0 / 0 |
brain | 18% | 0.63 | 471 / 2642 | 0% | 0 | 0 / 705 |
adipose | 17% | 1.32 | 199 / 1204 | 0% | 0 | 0 / 0 |
thymus | 16% | 0.59 | 107 / 653 | 0% | 0 | 0 / 605 |
esophagus | 14% | 0.61 | 208 / 1445 | 0% | 0 | 0 / 183 |
muscle | 11% | 0.31 | 91 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 10% | 0.37 | 128 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2001299 | Biological process | N(omega),N(omega)-dimethyl-L-arginine catabolic process |
GO_0019265 | Biological process | glycine biosynthetic process, by transamination of glyoxylate |
GO_0045429 | Biological process | positive regulation of nitric oxide biosynthetic process |
GO_0009436 | Biological process | glyoxylate catabolic process |
GO_0019481 | Biological process | L-alanine catabolic process, by transamination |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005739 | Cellular component | mitochondrion |
GO_0047305 | Molecular function | (R)-3-amino-2-methylpropionate-pyruvate transaminase activity |
GO_0016223 | Molecular function | beta-alanine-pyruvate transaminase activity |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
GO_0008453 | Molecular function | alanine-glyoxylate transaminase activity |
Gene name | AGXT2 |
Protein name | Alanine--glyoxylate aminotransferase 2, mitochondrial (EC 2.6.1.18) (EC 2.6.1.40) (EC 2.6.1.44) ((R)-3-amino-2-methylpropionate--pyruvate transaminase) (Beta-ALAAT II) (Beta-alanine-pyruvate aminotransferase) (D-3-aminoisobutyrate-pyruvate aminotransferase) (D-AIBAT) (D-beta-aminoisobutyrate-pyruvate aminotransferase) Alanine--glyoxylate aminotransferase 2, mitochondrial (AGT 2) (EC 2.6.1.44) ((R)-3-amino-2-methylpropionate--pyruvate transaminase) (EC 2.6.1.40) (Beta-ALAAT II) (Beta-alanine-pyruvate aminotransferase) (EC 2.6.1.18) (D-3-aminoisobutyrate-pyruvate aminotransferase) (D-AIBAT) (D-beta-aminoisobutyrate-pyruvate aminotransferase) |
Synonyms | AGT2 |
Description | FUNCTION: Multifunctional aminotransferase with a broad substrate specifcity . Catalyzes the conversion of glyoxylate to glycine using alanine as the amino donor (By similarity). Catalyzes metabolism of not L- but the D-isomer of D-beta-aminoisobutyric acid to generate 2-methyl-3-oxopropanoate and alanine . Catalyzes the transfer of the amino group from beta-alanine to pyruvate to yield L-alanine and 3-oxopropanoate (By similarity). Can metabolize NG-monomethyl-L-arginine (NMMA), asymmetric NG,NG-dimethyl-L-arginine (ADMA) and symmetric NG,N'G-dimethyl-L-arginine (SDMA) . ADMA is a potent inhibitor of nitric-oxide (NO) synthase, and this activity provides mechanism through which the kidney regulates blood pressure . . |
Accessions | ENST00000618015.4 [Q9BYV1-2] Q9BYV1 B2RBJ5 ENST00000231420.11 [Q9BYV1-1] ENST00000510428.1 [Q9BYV1-2] |